Appendix 3 (as supplied by the authors): Primary and secondary analyses with and without adjustment for angiotensin receptor blocker dose

	Adjusted hazard ratio (95% CI) (without dose)	Adjusted hazard ratio (95% CI) (with dose as time-dependent covariate)
Primary analysis		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.85 (0.74 to 0.97)	0.85 (0.73 to 0.98)
Candesartan	0.99 (0.89 to 1.11)	1.01 (0.89 to1.15)
Losartan	0.93 (0.83 to 1.05)	0.96 (0.83 to 1.10)
Valsartan	0.86 (0.77 to 0.96)	0.88 (0.77 to 1.00)
Secondary analysis #1: Myocardial infarction		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.92 (0.72 to 1.17)	0.99 (0.79 to 1.26)
Candesartan	1.01 (0.82 to 1.23)	1.00 (0.79 to 1.26)
Losartan	0.96 (0.78 to 1.20)	0.97 (0.76 to 1.26)
Valsartan	0.85 (0.70 to 1.04)	0.85 (0.68 to 1.07)
Secondary analysis #2: Stroke/TIA		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.84 (0.66 to 1.08)	0.84 (0.64 to 1.10)
Candesartan	0.98 (0.80 to 1.20)	1.01 (0.79 to 1.27)
Losartan	0.90 (0.72 to 1.12)	0.93 (0.72 to 1.21)
Valsartan	0.90 (0.74 to 1.09)	0.93 (0.74 to 1.17)

Secondary analysis #3: Heart Failure		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.80 (0.66 to 0.96)	0.78 (0.63 to 0.95)
Candesartan	1.02 (0.88 to 1.19)	1.09 (0.92 to 1.29)
Losartan	0.98 (0.84 to 1.15)	1.06 (0.88 to 1.28)
Valsartan	0.87 (0.75 to 1.01)	0.93 (0.78 to 1.10)
Secondary analysis #4: All cause-mortality		
Irbesartan (reference)	1.00	1.00
Telmisartan	0.95 (0.83 to 1.09)	0.93 (0.81 to 1.08)
Candesartan	1.05 (0.94 to 1.17)	1.06 (0.93 to 1.20)
Losartan	0.99 (0.87 to 1.11)	0.99 (0.86 to 1.14)
Valsartan	0.90 (0.80 to 1.00)	0.90 (0.79 to 1.03)